# Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

> **NCT00299494** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 119 (actual)

## Conditions studied

- B-Cell Lymphoma

## Interventions

- **DRUG:** inotuzumab ozogamicin
- **DRUG:** inotuzumab ozogamicin
- **DRUG:** inotuzumab ozogamicin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00299494
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-04
- **Primary completion:** 2014-05-19
- **Final completion:** 2014-06-02
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2018-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00299494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00299494, "Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00299494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*